Embecta 's ROA from the third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Embecta 's ROA in the third quarter of 2026?
Embecta Corp achieved a return on average assets (ROA) of 7.82 % in its third quarter of 2026, which is below Embecta 's average return on assets, which stands at 9.27%.

ROA fell compared to the second quarter of 2026, despite the net income growth of % from the second quarter of 2026.

However, within the Healthcare sector 120 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2026 from 540 to 588.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) III. Quarter	(Mar 31 2026) II. Quarter	(Dec 31 2025) I. Quarter	(Sep 30 2025) IV. Quarter	(Jun 30 2025) III. Quarter
Y / Y Total Assets Change	9.33 %	-8.11 %	-15.12 %	-15.12 %	-8.69 %
Y / Y Net Income Change	-53.63 %	-	-	80.82 %	209.52 %
Net Income (TTM) in million	88	112	140	95	84
Return On Assets (TTM)	7.82 %	10.25 %	12.51 %	8.2 %	6.9 %
EMBC's Total Ranking	# 588	# 540	#	#	#
Total Assets (TTM) in million	1,265	1,029	1,091	1,091	1,157
Seq. Total Assets Change	22.93 %	-5.65 %	0 %	-5.74 %	3.31 %
Seq. Net Income Change	-	-	67.05 %	-41.98 %	93.62 %

EMBC's 5 Years Annual ROA >> Back to EMBC Management Effectiveness >> Compare EMBC ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 35
Sector	# 121
Overall	# 785

Return On Assets Statistics
High	Average	Low
24.11 %	9.27 %	4.07 %
(Sep 30 2022)		(Jun 30 2023)

Financial Statements
Embecta 's Assets	$ 1,265 million	EMBC's Balance sheet
Embecta 's Income	$ 21 million	Quarterly EMBC's Income Statement
EMBC's Income by Division		See EMBC's Income by Division

Annual Return On Assets	(Sep 30 2025) FY 2025	(Sep 30 2024) FY 2024	(Sep 30 2023) FY 2023	(Sep 30 2022) FY 2022	FY
Y / Y Total Assets Change	-15.12 %	5.84 %	11.78 %	-	-
Total Assets in million	1,091	1,285	1,214	1,086	0
Y / Y Net Income Change	21.84 %	11.22 %	-68.52 %	-	-
Net Income in million	95	78	70	224	0
Annual Return On Assets	8.75 %	6.09 %	5.8 %	20.58 %	-

EMBC's 5 Years Annual ROA >> Back to EMBC Management Effectiveness >> Compare EMBC ROA to its Competitors

Comment on EMBC's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 8.75 % compared to prior year, due to annual net income growth of 21.84 % to $95.40 million, and due to decline of value in Embecta 's assets by -15.12 % to $1,090.90 million, compared to $1,090.90 a year before.

More Return On Assets Ratios
EMBC's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
EMBC's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EMBC's Competitors
Subscribers only: Roa for Embecta 's Suppliers
Subscribers only: Return On Assets for EMBC's Customers

You may also want to know
EMBC's Roi	EMBC's Inventory Turnover Ratio	EMBC's Growth Rates	EMBC's Dividend Comparisons
	EMBC's Profitability Ratios	EMBC's Asset Turnover Ratio	EMBC's Dividend Growth
EMBC's Roe	EMBC's Valuation Ratios	EMBC's Financial Strength Ratios	EMBC's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %
Standard Biotools Inc	14.31 %
Arcutis Biotherapeutics Inc	14.23 %
Harmony Biosciences Holdings inc	14.15 %
Biolife Solutions Inc	14.09 %
Aveanna Healthcare Holdings Inc	13.82 %
West Pharmaceutical Services Inc	13.64 %
Medinotec Inc	13.38 %
Puma Biotechnology Inc	13.28 %
Sbc Medical Group Holdings Incorporated	13.26 %
Alpha Pro Tech Ltd	13.17 %

Date modified: 2026-09-08T17:34:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.